Limiting sarcolemmal Na+ entry during resuscitation from ventricular fibrillation prevents excess mitochondrial Ca2+ accumulation and attenuates myocardial injury

J Appl Physiol (1985). 2007 Jul;103(1):55-65. doi: 10.1152/japplphysiol.01167.2006. Epub 2007 Apr 12.

Abstract

Background: intracellular Na+ accumulation during ischemia and reperfusion leads to cytosolic Ca2+ overload through reverse-mode operation of the sarcolemmal Na+ -Ca2+ exchanger. Cytosolic Ca2+ accumulation promotes mitochondrial Ca2+ (Ca2+ m) overload, leading to mitochondrial injury. We investigated whether limiting sarcolemmal Na+ entry during resuscitation from ventricular fibrillation (VF) attenuates Ca2+ m overload and lessens myocardial dysfunction in a rat model of VF and closed-chest resuscitation.

Methods: hearts were harvested from 10 groups of 6 rats each representing baseline, 15 min of untreated VF, 15 min of VF with chest compression given for the last 5 min (VF/CC), and 60 min postresuscitation (PR). VF/CC and PR included four groups each randomized to receive before starting chest compression the new NHE-1 inhibitor AVE4454B (1.0 mg/kg), the Na+ channel blocker lidocaine (5.0 mg/kg), their combination, or vehicle control. The left ventricle was processed for intracellular Na+ and Ca2+ m measurements.

Results: limiting sarcolemmal Na+ entry attenuated cytosolic Na+ increase during VF/CC and the PR phase and prevented Ca2+ m overload yielding levels that corresponded to 77% and 71% of control hearts at VF/CC and PR, without differences among specific Na+ -limiting interventions. Limiting sarcolemmal Na+ entry attenuated reductions in left ventricular compliance during VF and prompted higher mean aortic pressure (110 +/- 7 vs. 95 +/- 11 mmHg, P < 0.001) and higher cardiac work index (159 +/- 34 vs. 126 +/- 29 g x m x min(-1) x kg(-1), P < 0.05) with lesser increases in circulating cardiac troponin I at 60 min PR.

Conclusions: Na+ -limiting interventions prevented excess Ca2+ m accumulation induced by ischemia and reperfusion and ameliorated myocardial injury and dysfunction.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Anti-Arrhythmia Agents / pharmacology
  • Anti-Arrhythmia Agents / therapeutic use
  • Blood Pressure
  • Calcium / metabolism*
  • Coronary Circulation
  • Disease Models, Animal
  • Heart Ventricles / metabolism
  • Lidocaine / pharmacology
  • Lidocaine / therapeutic use
  • Male
  • Mitochondria, Heart / drug effects
  • Mitochondria, Heart / metabolism*
  • Myocardial Reperfusion Injury / etiology
  • Myocardial Reperfusion Injury / metabolism
  • Myocardial Reperfusion Injury / physiopathology
  • Myocardial Reperfusion Injury / prevention & control*
  • Myocardium / metabolism*
  • Myocardium / pathology
  • Rats
  • Rats, Sprague-Dawley
  • Research Design
  • Resuscitation*
  • Sarcolemma / drug effects
  • Sarcolemma / metabolism*
  • Sodium / metabolism*
  • Sodium Channel Blockers / pharmacology
  • Sodium Channel Blockers / therapeutic use
  • Sodium-Hydrogen Exchanger 1
  • Sodium-Hydrogen Exchangers / antagonists & inhibitors
  • Sodium-Hydrogen Exchangers / metabolism
  • Sodium-Potassium-Exchanging ATPase / metabolism
  • Troponin I / blood
  • Ventricular Fibrillation / complications
  • Ventricular Fibrillation / drug therapy
  • Ventricular Fibrillation / metabolism
  • Ventricular Fibrillation / physiopathology
  • Ventricular Fibrillation / therapy*
  • Ventricular Function, Left

Substances

  • Anti-Arrhythmia Agents
  • Slc9a1 protein, rat
  • Sodium Channel Blockers
  • Sodium-Hydrogen Exchanger 1
  • Sodium-Hydrogen Exchangers
  • Troponin I
  • Lidocaine
  • Sodium
  • Sodium-Potassium-Exchanging ATPase
  • Calcium